oncology-cancer-therapy-2019-posters-abstracts

Page 48

Notes:

allied

academies

Journal of Medical Oncology & Therapeutics | Volume 4

March 18-19, 2019 | London, UK

Oncology & Cancer Therapy

International Conference on

Genetic and imaging factors affecting renal cell carcinoma survival

Ecem Altay

and

Albert Guvenis

Bogazici University, Turkey

enal cell carcinoma (RCC), the most common type

of kidney cancers, is the most deadly of urological

malignancies. Scientists are studying to understand the renal

cell carcinoma mechanism in order to improve treatment

options and to provide patients longer and higher-quality

lifetime. In this research, factors that affect renal cell

carcinoma survival are studied in order to shed light on

controversies in the literature, and these factors are mostly

mutated gene (VHL) and imaging feature (tumor stage). The

Cancer Genome Atlas and The Cancer Imaging Archive were

used to obtain patient genetic and imaging data. Kaplan-

Meier method and log-rank test were applied to evaluate

the effect of genetic and imaging factors on survival of RCC

patients. The effect of presence of mutated VHL gene at

different stage levels has been evaluated (P=0.602 for stage

I, P=0.005 for stage IV). The results show that at stage I, VHL

did not change the survival rate in our study. However, at

stage IV, RCC patients who have mutated VHL gene have

longer survival. Determining the factors affecting survival

will help develop personalized treatments. The survival’s

association with therapeutic choices, image phenotypes and

genetic factors follow complex relationships. It is therefore

concluded that the few initial radiomics and radiogenomics

studies should be pursued further. These studies have the

potential to generate the reliable computer aided predictive

models of survival and genetic mutations from patient image

features.